mAbs (biosimilars) as tools to research novel new therapies and uncover effective off-target application.
Monoclonal Antibody Drugs for Cancer
Monoclonal antibody drugs have emerged as powerful tools in the fight against cancer, revolutionising treatment approaches.
Insights into the Molecular Mechanisms Regulating Necroptosis
This white paper details findings in molecular mechanisms that govern necroptosis related to RIPK & details #2283 use to analyse expression of RIPK3.
PD-1: Expanding Beyond Cancer Research
ProSci details the importance of PD-1 antibodies are important in resolving complex interactions between the immune system & pathological conditions.
Protein Phosphorylation: Essential Role in the Proper Functioning of Pathways
MBLI offers Assay/Inhibitor screening kits designed to measure the activities of purified kinase for the rapid and sensitive evaluation of inhibitors.
New B7 Family Immune Checkpoint Proteins
Recently 5 new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 & B7-H7, were identified, all of them possibly of high interest in immunotherapy research.
HVEM – BTLA – LIGHT – CD160 Network
The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions.
OX40 – OX40L Pathway
OX40 is an activating receptor expressed on the surface of activated cytotoxic T cells & Tregs. OX40 activates & amplifies T cell responses.
TIGIT – CD155 – CD112 – CD226 Network
Tumour cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction.
LAG-3 – Major Histocompatibility Complex (MHC) – T Cell Receptor (TCR) Pathway
Dual inhibition of LAG-3 and other checkpoint pathways may synergistically increase T cell antitumour activity.